39 results on '"Ye, Xingnong"'
Search Results
2. Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
3. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study
4. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex
5. Clinical Characteristics and Prognosis of Patients with Follicular Lymphoma Grade 3A: A real-world study in a single centre
6. Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival.
7. Inactivated Vaccine Dosage and Serum IgG Levels Correlate with Persistent COVID-19 Infection in Hematologic Malignancy Patients During the Omicron Surge in China
8. Continuous Therapy in HHV-8 Negative Multicentric Castleman Disease: Pioneering Prolonged Progression-Free Survival
9. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy
10. Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML
11. Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases
12. Venetoclax plus ‘2 + 5’ modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single‐centre retrospective analysis
13. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex
14. Venetoclax Plus "2 + 5" Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis
15. EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes
16. Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone
17. Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases
18. A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation
19. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study
20. Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
21. Next-Generation Sequencing Mutational Landscape and Clinical Features of Chinese Adults with Myeloproliferative Neoplasms
22. Uncommon Hpgd Mutation Identified in Familial Erythrocytosis
23. Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
24. PML‐RARA monitoring in newly diagnosed acute promyelocytic leukemia treated with an entirely oral chemotherapy‐free postremission approach: A multiple institution experience
25. Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up
26. Co-existence of myeloproliferative neoplasias and β-thalassemia with IVS-2-654 mutation—a case report
27. BCOR Mutation and TLS-ERG Expression in Acute Myeloid Leukemia with Monoclonal Immunoglobulinemia
28. BCOR mutation and TLS-ERG expression in acute myeloid leukemia with monoclonal immunoglobulinemia
29. Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen
30. The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population‐based study
31. Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
32. Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
33. How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia
34. Small-Dose Trimethoprim-Sulfamethoxazole Prevents Pneumocystis Jiroveci Pneumonia in B-Cell Lymphoma Patients Receiving Chemotherapy: Analysis of a Randomized Controlled Clinical Trial
35. Venetoclax Plus ‘2 + 5‘ Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukaemia: A Single-Centre Retrospective Analysis
36. Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study
37. Effective Treatment of Low-Doses Decitabine in Myelodysplastic Syndrome / Myeloproliferative Neoplasms with JAK2/V617F
38. Gender and Marital Status Influence Survival of Myelodysplastic Syndrome and Risk of Secondary Acute Myeloid Leukemia: A Population-Based Study of Patients in the Surveillance, Epidemiology, and End Results (SEER) Database
39. Case Report: Diagnosis of Hemolytic Anemia from Babesia and Secondary Multi-Pathogen Pneumonia Using a Metagenomic Next-Generation Sequencing Approach.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.